PACIRA BIOSCIENCES, INC. Interest Expense Nonoperating
PACIRA BIOSCIENCES, INC. (PCRX) reported Interest Expense Nonoperating of $3.62 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-04
- PACIRA BIOSCIENCES, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $3.62M, a 22.85% decline year-over-year.
- PACIRA BIOSCIENCES, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $3.70M, a 19.24% decline year-over-year.
- PACIRA BIOSCIENCES, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $3.89M, a 16.84% decline year-over-year.
- PACIRA BIOSCIENCES, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $4.28M, a 8.74% decline year-over-year.
- PACIRA BIOSCIENCES, INC. interest expense nonoperating for fiscal 2025 was $17.45M, a 5.29% increase from fiscal 2024.
- PACIRA BIOSCIENCES, INC. interest expense nonoperating for fiscal 2024 was $16.57M, a 18.40% decline from fiscal 2023.
- PACIRA BIOSCIENCES, INC. interest expense nonoperating for fiscal 2023 was $20.31M, a 49.20% decline from fiscal 2022.
- PACIRA BIOSCIENCES, INC. interest expense nonoperating for fiscal 2022 was $39.98M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.62M 10-Q · filed 2026-08-04 | $7.32M 10-Q · filed 2026-08-04 | $11.21M derived: sum of 3 quarters · filed 2026-08-04 | $15.49M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $3.70M 10-Q · filed 2026-04-30 | $7.59M derived: sum of 2 quarters · filed 2026-04-30 | $11.87M derived: sum of 3 quarters · filed 2026-04-30 | $16.57M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $3.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $8.17M derived: sum of 2 quarters · filed 2026-02-26 | $12.87M derived: sum of 3 quarters · filed 2026-08-04 | $17.45M 10-K · filed 2026-02-26 |
| 2025-09-30 | $4.28M 10-Q · filed 2025-11-06 | $8.97M derived: sum of 2 quarters · filed 2026-08-04 | $13.55M 10-Q · filed 2025-11-06 | $18.23M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $4.70M 10-Q · filed 2026-08-04 | $9.28M 10-Q · filed 2026-08-04 | $13.96M derived: sum of 3 quarters · filed 2026-08-04 | $18.64M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $4.58M 10-Q · filed 2026-04-30 | $9.26M derived: sum of 2 quarters · filed 2026-04-30 | $13.95M derived: sum of 3 quarters · filed 2026-04-30 | $17.83M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $4.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $9.37M derived: sum of 2 quarters · filed 2026-02-26 | $13.25M derived: sum of 3 quarters · filed 2026-02-26 | $16.57M 10-K · filed 2026-02-26 |
| 2024-09-30 | $4.69M 10-Q · filed 2025-11-06 | $8.57M derived: sum of 2 quarters · filed 2025-11-06 | $11.89M 10-Q · filed 2025-11-06 | $15.28M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $3.88M 10-Q · filed 2025-08-05 | $7.20M 10-Q · filed 2025-08-05 | $10.59M derived: sum of 3 quarters · filed 2026-02-26 | $14.05M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $3.32M 10-Q · filed 2025-05-08 | $6.70M derived: sum of 2 quarters · filed 2026-02-26 | $10.17M derived: sum of 3 quarters · filed 2026-02-26 | $14.03M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $3.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.85M derived: sum of 2 quarters · filed 2026-02-26 | $10.72M derived: sum of 3 quarters · filed 2026-02-26 | $20.31M 10-K · filed 2026-02-26 |
| 2023-09-30 | $3.46M 10-Q · filed 2024-11-06 | $7.33M derived: sum of 2 quarters · filed 2024-11-06 | $16.92M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $3.87M 10-Q · filed 2024-07-30 | $13.45M 10-Q · filed 2024-07-30 | ||
| 2022-12-31 | $39.98M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |